Zenas BioPharma (ZBIO) reported second-quarter 2026 revenue of $1.0 million and a net loss of $111.5 million, compared with a $52.2 million net loss in the prior-year quarter. Basic and diluted net loss per share was $1.77.
The company ended June 30, 2026, with $673.9 million in cash, cash equivalents and investments. The FDA accepted Zenas' biologics license application for obexelimab in IgG4-related disease, with a PDUFA target action date of May 27, 2027.
- Second-quarter R&D expense was $62.9 million, versus $43.0 million a year earlier.
- G&A expense was $15.7 million, compared with $12.1 million in the prior-year quarter.
- Acquired in-process R&D expense totaled $30.0 million.
- Topline Phase 2 SunStone trial results for obexelimab in SLE are expected in the fourth quarter of 2026.
- Initial Phase 1 data for ZB021 are expected by year-end 2026.
$ZBIO Insider Trading Activity
$ZBIO insiders have traded $ZBIO stock on the open market 12 times in the past 6 months. Of those trades, 12 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $ZBIO stock by insiders over the last 6 months:
- LEON O JR MOULDER (Chief Executive Officer) has made 5 purchases buying 174,000 shares for an estimated $3,101,140 and 0 sales.
- FUNDS MANAGEMENT LLC FAIRMOUNT purchased 150,000 shares for an estimated $3,000,000
- HONGBO LU has made 2 purchases buying 78,768 shares for an estimated $1,570,197 and 0 sales.
- PATRICIA L ALLEN has made 4 purchases buying 19,860 shares for an estimated $499,745 and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$ZBIO Hedge Fund Activity
We have seen 99 institutional investors add shares of $ZBIO stock to their portfolio, and 57 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- NOVO HOLDINGS A/S removed 2,000,000 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $39,100,000
- POLAR CAPITAL HOLDINGS PLC added 1,490,835 shares (+141.0%) to their portfolio in Q1 2026, for an estimated $29,145,824
- FMR LLC added 1,377,745 shares (+17.9%) to their portfolio in Q1 2026, for an estimated $26,934,914
- SILVERARC CAPITAL MANAGEMENT, LLC added 1,135,935 shares (+inf%) to their portfolio in Q1 2026, for an estimated $22,207,529
- ALLIANCEBERNSTEIN L.P. added 878,971 shares (+4790.0%) to their portfolio in Q1 2026, for an estimated $17,183,883
- BLACKROCK, INC. added 648,677 shares (+31.8%) to their portfolio in Q2 2026, for an estimated $16,463,422
- WOODLINE PARTNERS LP added 590,525 shares (+inf%) to their portfolio in Q1 2026, for an estimated $11,544,763
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
